Stage 2 prostate adenocarcinoma is localized, with a nearly 100% five-year relative survival rate. Diagnosis uses the TNM system, PSA levels, and Gleason score to determine cancer stage and risk.
Stage 1 prostate adenocarcinoma is localized, non-aggressive, and often detected through routine screenings like PSA tests and DREs. Diagnosis involves PSA levels, Gleason scores, and possibly ...
Among prostate cancer patients with a luminal B subtype, the 5-year biochemical progression-free survival rate was 72% in the apalutamide group and 54% in the placebo group. Recurrent prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback